ObjectiveTo investigate the expression profiles of sphingolipids in peripheral serum in patients with hepatitis B/C cirrhosis and those with non-viral hepatitis-related cirrhosis. MethodsA total of 104 patients with liver cirrhosis who were admitted to Difficult & Complicated Liver Diseases and Artificial Liver Center, Beijing YouAn Hospital, Capital Medical University, from July 2014 to May 2015 were enrolled as subjects, and finally 97 patients with liver cirrhosis were enrolled, among whom there were 66 patients (68.04%) with hepatitis B/C cirrhosis and 31 patients (31.96%) with non-viral hepatitis-related cirrhosis. High-performance liquid chromatography-mass spectrometry was used to measure the expression of 57 sphingolipids in peripheral serum. The t-test or the Mann-Whitney U test was used for comparison of continuous data between two groups, and the chi-square test was used for comparison of categorical data between two groups. The variables with statistical significance in the univariate analysis were included in the multivariate analysis. ResultsThere were no significant differences between the two groups in age, proportion of male patients, total bilirubin, direct bilirubin, and gamma-glutamyl transpeptidase (all P>0.05). As for the 57 sphingolipids in peripheral serum, compared with the non-viral hepatitis-related cirrhosis group, the viral hepatitis-related cirrhosis group had significantly higher expression of Cer(d18∶1/12∶0) [168.61 (16854-168.88) pmol/0.1 ml vs 168.53 (168.48-168.63) pmol/0.1 ml, Z=-2.54, P<0.05], HexCer (d18∶1/14∶1) [213.93 (211.15-218.92) pmol/0.1 ml vs 212.26 (209.90-214.64) pmol/0.1 ml, Z=-2.03, P<0.05], and dhCer(d18∶0/24∶1)-1-P [60.07 (59.40-61.23) pmol/0.1 ml vs 59.42 (59.28-59.87) pmol/0.1 ml, Z=-2.32, P<0.05]. The logistic regression analysis revealed that high expression of dhCer(d18∶0/24∶1)-1-P was independently associated with hepatitis B/C cirrhosis (odds ratio=111, 95% confidence interval: 1.004-1.225, P=0.042). The subgroup analysis of the patients with viral hepatitis-associated cirrhosis showed that there were no significant differences between the patients with hepatitis B cirrhosis and those with hepatitis C cirrhosis in the expression of Cer(d18∶1/12∶0), HexCer (d18∶1/14∶1), and dhCer(d18∶0/24∶1)-1-P (Z=-0.563, -0.610, and -0.579, all P>0.05). ConclusionThe sphingolipid dhCer (d18∶0/24∶1)-1-P in peripheral serum is closely associated with hepatitis B/C cirrhosis and may help to understand the features of viral hepatitis-related cirrhosis from the perspective of sphingolipids.
[1]SINN DH,LEE J,GOO J,et al.Hepatocellular carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low viral load[J].Hepatology,2015,62(3)∶694-701.
|
[2]MARM,FERNNDEZ-CHECA JC.Sphingolipid signalling and liver diseases[J].Liver Int,2007,27(4):440-450.
|
[3]FERNANDEZ A,MATIAS N,FUCHO R,et al.ASMase is required for chronic alcohol induced hepatic endoplasmic reticulum stress and mitochondrial cholesterol loading[J].J Hepatol,2013,59(4):805-813.
|
[4]TONG M,LONGATO L,RAMIREZ T,et al.Therapeutic reversal of chronic alcohol-related steatohepatitis with the ceramide inhibitor myriocin[J].Int J Exp Pathol,2014,95(1):49-63.
|
[5]PRALHADA RAO R,VAIDYANATHAN N,RENGASAMY M,et al.Sphingolipid metabolic pathway:An overview of major roles played in human diseases[J].J Lipids,2013,2013:178910.
|
[6]GRAMMATIKOS G,SCHOELL N,FERREIRS N,et al.Serum sphingolipidomic analyses reveal an upregulation of C16-ceramide and sphingosine-1-phosphate in hepatocellular carcinoma[J].Oncotarget,2016,7(14):18095-18105.
|
[7]WU T,ZHENG X,YANG M,et al.Serum lipid alterations identified in chronic hepatitis B,hepatitis B virus-associated cirrhosis and carcinoma patients[J].Sci Rep,2017,7:42710.
|
[8]DJIAMBOU-NGANJEU H.Hepatic encephalopathy in liver cirrhosis[J].J Transl Int Med,2017,5(1):64-67.
|
[9]NOSRATABADI R,ALAVIAN SM,ZARE-BIDAKI M,et al.Innate immunity related pathogen recognition receptors and chronic hepatitis B infection[J].Mol Immunol,2017,90:64-73.
|
[10]XU Y,ZHONG J.Innate immunity against hepatitis C virus[J].Curr Opin Immunol,2016,42:98-104.
|
[11]LI K,LI NL,WEI D,et al.Activation of chemokine and inflammatory cytokine response in hepatitis C virus-infected hepatocytes depends on Toll-like receptor 3 sensing of hepatitis Cvirus double-stranded RNA intermediates[J].Hepatology,2012,55(3):666-675.
|
[12]QU F,ZHENG SJ,LIU S,et al.Serum sphingolipids reflect the severity of chronic HBV infection and predict the mortality of HBV-acute-on-chronic liver failure[J].PLo S One,2014,9(8):e104988.
|
[13]ZHANG JY,QU F,LI JF,et al.Up-regulation of plasma hexosylceramide (d18∶1/18∶1) contributes to genotype 2 virus replication in chronic hepatitis C:A 20-year cohort study[J].Medicine (Baltimore),2016,95(23):e3773.
|
[14]CINGOLANI F,SIMBARI F,ABAD JL,et al.Jaspine B induces nonapoptotic cell death in gastric cancer cells independently of its inhibition of ceramide synthase[J].J Lipid Res,2017,58(8):1500-1513.
|
[15]OLSEN I,NICHOLS FC.Are sphingolipids and serine dipeptide lipids underestimated virulence factors of porphyromonas gingivalis?[J].Infect Immun,2018,86(7):e00035-18.
|
[16]NICHOLS FC,HOUSLEY WJ,O’CONOR CA,et al.Unique lipids from a common human bacterium represent a new class of Toll-like receptor 2 ligands capable of enhancing autoimmunity[J].Am J Pathol,2009,175(6):2430-2438.
|
[17]NICHOLS FC,YAO X,BAJRAMI B,et al.Phosphorylated dihydroceramides from common human bacteria are recovered in human tissues[J].PLo S One,2011,6(2):e16771.
|